Skip to main content
NVDA-1.17%AAPL+0.81%GOOGL+0.30%MSFT+0.11%AMZN-0.01%TSM+0.17%SPCX-4.21%META-0.81%AVGO+0.73%TSLA-0.81%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU-2.31%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.15%ASMLa+0.13%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.42%ABBV-2.42%1398.HK-0.92%CSCO-0.23%CVX+1.32%COST-0.50%ORCL+4.24%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%AP2d+0.34%PG-0.10%CAT-3.33%1816.HK+2.71%UNH-0.20%3988.HK-1.12%0005.HK-1.79%0857.HK+1.17%HSBA.L-1.27%GE-0.33%PM-1.34%0939.HK-1.00%1288.HK-2.23%MS-1.77%NFLX-0.21%USDSEK+0.93%USDCHF+0.92%USDMXN+0.86%CADCHF+0.76%EURUSD-0.72%USDDKK+0.70%EURHKD-0.69%USDPLN+0.67%AUDCHF+0.63%GBPCHF+0.61%EURCNH-0.59%USDZAR+0.58%EURCAD-0.58%CHFJPY-0.54%NZDUSD-0.52%USDTHB+0.52%USDSGD+0.50%EURAUD-0.42%GBPTRY+0.41%AUDDKK+0.40%EURGBP-0.40%NZDCAD-0.39%EURNOK-0.37%USDJPY+0.37%NZDCHF+0.37%EURJPY-0.35%USDNOK+0.33%GBPHKD+0.32%GBPUSD-0.32%CHFSEK+0.31%NZDMXN+0.31%PLNJPY-0.30%AUDUSD-0.29%CHFNOK-0.29%GBPMXN-0.28%USDTRY+0.28%AUDNZD+0.26%EURSEK+0.23%GBPNZD+0.21%EURSGD-0.20%AUDSGD+0.20%CADJPY+0.19%EURCHF+0.18%NZDJPY-0.18%USDCAD+0.17%USDILS+0.16%EURNZD-0.16%GBPCAD-0.14%SGDJPY-0.14%AUDCAD-0.13%CHFSGD-0.12%EURZAR-0.11%GBPZAR+0.10%USDCNH+0.10%EURCZK+0.08%AUDJPY+0.07%NZDSGD-0.06%GBPJPY+0.04%USDCOP-0.04%NOKJPY+0.03%AUDNOK+0.03%EURPLN-0.03%GBPSGD+0.02%GBPAUD-0.01%USDHKD+0.01%EURDKK+0.01%GAGUSD-3.94%XAGUSD-3.93%COFFEE+2.90%XPTUSD-1.86%XAUUSD-1.71%GAUUSD-1.70%XNGUSD-1.49%COCOA+1.40%COTTON+1.03%SUGAR-0.71%USOIL+0.62%HG1-0.56%BTCUSD-0.52%ETHUSD+15.24%USDTUSD-0.02%XRPUSD+9.86%SOLUSD+10.90%TRXUSDT+1.91%ZECUSDT-0.18%DOGEUSD+11.12%XMRUSDT+0.75%LINKUSD+11.09%XLMUSD-1.73%BCHUSDT-0.26%LTCUSD+9.37%UNIUSD-4.20%SUIUSD-1.85%HBARUSDT-2.00%TONUSD+24.80%TAOUSDT-1.55%AAVEUSD-1.47%DOTUSDT-1.05%ICPUSDT-2.44%ONDOUSDT-3.38%WLDUSDT-3.65%ARBUSDT-3.64%JUPUSDT-3.16%ATOMUSDT-3.16%INJUSDT-3.35%STXUSDT-2.63%FETUSDT-2.05%PYTHUSDT+6.92%TIAUSDT-5.09%SEIUSDT-3.09%IMXUSDT-4.22%OPUSDT-8.66%GRTUSDT-2.95%WIFUSDT-2.74%IOTAUSDT-3.61%AXSUSDT-3.30%POLUSDT-3.86%FARTCOINUSDT-4.13%EOSUSDT+2.75%DYDXUSDT-4.43%GALAUSDT-4.04%ORDIUSDT-3.09%RONINUSDT-4.26%NOTUSDT-3.35%NVDA-1.17%AAPL+0.81%GOOGL+0.30%MSFT+0.11%AMZN-0.01%TSM+0.17%SPCX-4.21%META-0.81%AVGO+0.73%TSLA-0.81%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU-2.31%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.15%ASMLa+0.13%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.42%ABBV-2.42%1398.HK-0.92%CSCO-0.23%CVX+1.32%COST-0.50%ORCL+4.24%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%AP2d+0.34%PG-0.10%CAT-3.33%1816.HK+2.71%UNH-0.20%3988.HK-1.12%0005.HK-1.79%0857.HK+1.17%HSBA.L-1.27%GE-0.33%PM-1.34%0939.HK-1.00%1288.HK-2.23%MS-1.77%NFLX-0.21%USDSEK+0.93%USDCHF+0.92%USDMXN+0.86%CADCHF+0.76%EURUSD-0.72%USDDKK+0.70%EURHKD-0.69%USDPLN+0.67%AUDCHF+0.63%GBPCHF+0.61%EURCNH-0.59%USDZAR+0.58%EURCAD-0.58%CHFJPY-0.54%NZDUSD-0.52%USDTHB+0.52%USDSGD+0.50%EURAUD-0.42%GBPTRY+0.41%AUDDKK+0.40%EURGBP-0.40%NZDCAD-0.39%EURNOK-0.37%USDJPY+0.37%NZDCHF+0.37%EURJPY-0.35%USDNOK+0.33%GBPHKD+0.32%GBPUSD-0.32%CHFSEK+0.31%NZDMXN+0.31%PLNJPY-0.30%AUDUSD-0.29%CHFNOK-0.29%GBPMXN-0.28%USDTRY+0.28%AUDNZD+0.26%EURSEK+0.23%GBPNZD+0.21%EURSGD-0.20%AUDSGD+0.20%CADJPY+0.19%EURCHF+0.18%NZDJPY-0.18%USDCAD+0.17%USDILS+0.16%EURNZD-0.16%GBPCAD-0.14%SGDJPY-0.14%AUDCAD-0.13%CHFSGD-0.12%EURZAR-0.11%GBPZAR+0.10%USDCNH+0.10%EURCZK+0.08%AUDJPY+0.07%NZDSGD-0.06%GBPJPY+0.04%USDCOP-0.04%NOKJPY+0.03%AUDNOK+0.03%EURPLN-0.03%GBPSGD+0.02%GBPAUD-0.01%USDHKD+0.01%EURDKK+0.01%GAGUSD-3.94%XAGUSD-3.93%COFFEE+2.90%XPTUSD-1.86%XAUUSD-1.71%GAUUSD-1.70%XNGUSD-1.49%COCOA+1.40%COTTON+1.03%SUGAR-0.71%USOIL+0.62%HG1-0.56%BTCUSD-0.52%ETHUSD+15.24%USDTUSD-0.02%XRPUSD+9.86%SOLUSD+10.90%TRXUSDT+1.91%ZECUSDT-0.18%DOGEUSD+11.12%XMRUSDT+0.75%LINKUSD+11.09%XLMUSD-1.73%BCHUSDT-0.26%LTCUSD+9.37%UNIUSD-4.20%SUIUSD-1.85%HBARUSDT-2.00%TONUSD+24.80%TAOUSDT-1.55%AAVEUSD-1.47%DOTUSDT-1.05%ICPUSDT-2.44%ONDOUSDT-3.38%WLDUSDT-3.65%ARBUSDT-3.64%JUPUSDT-3.16%ATOMUSDT-3.16%INJUSDT-3.35%STXUSDT-2.63%FETUSDT-2.05%PYTHUSDT+6.92%TIAUSDT-5.09%SEIUSDT-3.09%IMXUSDT-4.22%OPUSDT-8.66%GRTUSDT-2.95%WIFUSDT-2.74%IOTAUSDT-3.61%AXSUSDT-3.30%POLUSDT-3.86%FARTCOINUSDT-4.13%EOSUSDT+2.75%DYDXUSDT-4.43%GALAUSDT-4.04%ORDIUSDT-3.09%RONINUSDT-4.26%NOTUSDT-3.35%
EB

Emergent BioSolutions Inc. (EBS)

NYSE • Healthcare

$6.91
-$0.07 (-1.0%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$6.95
Day Range$6.85 - $7.07
Avg. Volume (3M)1.1M
Market Cap$356.5M
52 Week Range
$4.36$14.06
Next EarningsIn 21 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$234.3M100%
Gross Profitminus cost of goods$137.2M59%

In plain terms: out of every $100 in revenue, Emergent BioSolutions Inc. currently loses $77.

Fundamentals & Financials

Revenue (TTM)
$770.2M
Net Income (TTM)
-$176.8M
EPS (TTM)
-$3.44
ROA (TTM)
-15.83%
Current Ratio
5.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-490.9%Q1 2026-$0.43
+184.0%Q2 2026$0.21
+805.9%Q3 2026$0.6
Next

Nov 4

in 21 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +805.9%

Emergent BioSolutions beat expectations on both the top and bottom line in preliminary second fiscal quarter of 2026 results reported Aug. 5, as revenue rose about 66% to about $234.3 million from about $140.9 million a year ago and topped the $177.5 million estimate by 32.0%. Adjusted EPS of $0.60 beat the -$0.09 estimate by 805.9% and was up 275% from $0.16 a year ago, while gross profit reached roughly $137.2 million and gross margin held near 59%. MCM Product sales led at about $168.0 million, up 188%, alongside USG at about $157.1 million, up 172%, while Commercial Product sales fell 22% to about $52.4 million. Operating cash flow was negative about $16.2 million, the company repurchased about $8.8 million of stock, and next-period consensus calls for EPS of $0.14 on revenue of $209.0 million.

Next report — what to expect

Emergent BioSolutions Inc. (EBS) reports on November 4, 2026. Wall Street is looking for consensus EPS of -$0.37 on revenue of $123.2 million. For trailing context, revenue rose +66.3% year over year last quarter. EBS has beaten EPS in 7 of 8 most recent quarters, making any variance from expectations a key focus.

View full earnings history

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. develops and supplies biodefense and public-health countermeasures in the healthcare and biotechnology field. Listed on the NYSE as EBS, it sells vaccines, therapeutics, medical countermeasures, and manufacturing services centered on U.S. government and health-security demand, and generated $742.9 million of revenue in FY2025.

Name
Emergent BioSolutions Inc.
CEO
Joseph C. Papa Jr.
Website
www.emergentbiosolutions.com
Industry
Healthcare
Year Founded
1998
Employees
900

Today's Snapshot

AI-generated

Yesterday EBS fell 1.0% to 6.91.

Trading Volume

Below 10d avg (1.1M)

576K

vs S&P 500 Today

Underperforming Market

-0.98%

Updated: October 14, 2026 at 12:21 UTC

Technical Indicators

4 Buy2 Neutral2 Sell
EBS shows a modest buy bias as short- and medium-term moving averages sit at or slightly below the current price while the 100- and 200-day averages remain higher, indicating mixed longer-term pressure. Momentum is neutral-to-positive with a small MACD bullish reading and RSI in the mid-50s, while ADX near 20 signals limited trend strength. Volatility is elevated relative to price (ATR around 5.6%), and on-balance volume is negative, tempering conviction. The classic pivot sits just above the market. Technical takeaway: modest buy supported by short/medium MA alignment and a bullish MACD, but longer-term averages and weak volume soften the case.
All signals
  • EMA (5 indicators)$6.63 - $8.24
    Buy
  • RSI (14)54.68
    Neutral
  • Stochastic %K (14, 3, 3)52.72
    Neutral
  • MACD Level (12, 26)0.19
    Buy

Peers & Related Assets

RIGLRigel Pharmaceuticals, Inc.
$47.14-3.4%
CRVSCorvus Pharmaceuticals, Inc.
$9.41-6.4%
ESPREsperion Therapeutics, Inc.
$3.180.0%
OLMAOlema Pharmaceuticals, Inc.
$7.02-4.6%
AQSTAquestive Therapeutics, Inc.
$4.67-2.9%
PRTAProthena Corporation plc
$8.36-0.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.